Health Care and Biotech

Primary Health Care, in streamlining its balance sheet, has signalled a downgrade to profit expectations for FY16. Brokers review the outlook.

Disruption ahead for financials; health care catalysts; ASX20 under performance and relative value; Bell Potter prefers insurers over banks and reviews Breville Group.

Fisher & Paykel Healthcare has extended its track record of beating guidance with a robust FY16 result and brokers expect more of the same in FY17.

The government and Pathology Australia have struck a deal on collection centre rents and brokers look at the implications for pathology providers.

Brokers laud the acquisition strategy of Integral Diagnostics, as it expands its regional footprint in Victoria.

Impact of the Commonwealth Budget; Origin’s power purchase; changes to aged care; growth in outdoor media; new property listings; Telstra and the NBN.

Hospital industry outlook; Vic gaming data; Morgan Stanley initiates on Pacific Smiles; US new home sales soften.

Outlook for general insurers; Commonwealth budget preview; Aldi’s success; banks and bad debts; GUD Holdings vs GWA Group; aged care sector review.

Shareholder returns; Amcor in Credit Suisse’s top picks; services exports; retail sales outlook, federal budget and healthcare reforms; Bell Potter initiates on Medical Developments International.

Pro Medicus has won a seven-year contract with the Mercy Health System and Moelis takes a look at what this means for the earnings outlook.